Sanofi Logo
CAD Logo

PATIENT SUPPORT AND FINANCIAL ASSISTANCE

Support in your corner with
ENJAYMO patient solutions
ENJAYMO Patient Solutions is here to help support you through your treatment journey. We're available to assist you Monday through Friday, 8 AM to 8 PM ET, at 1-833-223-2428.
Meet the team that’s ready to support you
When you enroll in ENJAYMO Patient Solutions, you gain access to a dedicated team that can connect you with education and a range of resources on ENJAYMO.
Case Managers
Case managers are experienced in helping individuals get started on treatment and assisting with insurance‑related needs. They are also an ongoing resource should you need additional support along the way.
Therapeutic education managers (TEMS)
Therapeutic Education Managers, or TEMs, are available to provide education about ENJAYMO and CAD. TEMs help raise awareness about CAD in the community and educate patients and caregivers. They engage with patients to provide information and facilitate educational events about ENJAYMO and CAD. Talk to your Case Manager to learn more about how to contact a TEM.
TEMs are paid to provide educational services on behalf of Sanofi. They do not provide medical advice. You should always talk to your doctor about any healthcare needs.
Financial Assistance Programs for eligible patients
The ENJAYMO Patient Solutions Financial Assistance Programs are designed to provide support for eligible patients who wouldn’t be able to access ENJAYMO otherwise. There are two options available:
The co-pay assistance program
ENJAYMO Co-Pay Assistance Program may be able to help with eligible patients' treatment costs, such as out-of-pocket, co-payments or co-insurance, and cost of infusion, if they meet the program requirements.*
The Patient assistance program
ENJAYMO Patient Assistance Program provides financial support for eligible patients who have limited access to treatment due to insurance issues and financial challenges.
The ENJAYMO Patient Solutions Co-Pay Program (the "Program") is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE® or similar federal or state programs, including any state pharmaceutical assistance programs. The Program is not valid where prohibited by law, and savings may vary depending on patients' out-of-pocket costs. Sanofi reserves the right to modify or terminate the Program at any time without notice. Patients will receive all Program details upon registration.
ATTEND AN EDUCATIONAL ENJAYMO EVENT
Find free in-person and online educational events to learn more about CAD and ENJAYMO.
INDICATION
ENJAYMO is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children
INDICATION & IMPORTANT SAFETY INFORMATION
IMPORTANT SAFETY INFORMATION
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
Serious Infections: ENJAYMO is a prescription medicine that affects your immune system. ENJAYMO can lower the ability of your immune system to fight infections. People who take ENJAYMO may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitides, Streptococcus pneumoniae , and Haemophilus influenzae . These infections may be serious or life-threatening. Some infections may quickly become life-threatening or cause death if not recognized and treated early.
You need to receive vaccinations against infections caused by certain kinds of bacteria at least 2 weeks before your first dose of ENJAYMO. You may need to have additional vaccinations during treatment
If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:
fever
severe headache with stiff neck or back
pain during urination or urinating more often than usual
cough or difficulty breathing
flu-like symptoms
pain, redness or swelling of the skin
Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction, and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including:
shortness of breath
rapid heartbeat
nausea
flushing
headache
Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:
joint pain or swelling
rash on the cheeks and nose
unexplained fever
If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD to return. Symptoms or problems that can happen due to red blood cell breakdown include:
tiredness
shortness of breath
rapid heart rate
blood in your urine or dark urine
The most common side effects of ENJAYMO include:
respiratory tract infection
viral infection
diarrhea
indigestion
cough
joint pain
joint inflammation (arthritis)
swelling of the lower legs, ankles, and feet
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:
have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.
are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Back to the top